Three double-blind , randomized , placebo-controlled , phaseI studies evaluated the pharmacokinetics of daclizumab HYP in healthy volunteers following single subcutaneous administration ( 50 , 150 , or 300mg ) , multiple subcutaneous administrations ( 100 or 200mg biweekly with a 200mg loading dose ) , or single intravenous administration ( 200 or 400mg ) .